TrialJapanese journal of clinical oncology2013

Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.

Takeshi Ueda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.